Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) – Equities research analysts at HC Wainwright decreased their Q3 2023 earnings per share estimates for shares of Celldex Therapeutics in a note issued to investors on Wednesday, August 9th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will earn ($0.69) per share for the quarter, down from their prior estimate of ($0.68). HC Wainwright currently has a “Buy” rating and a $73.00 target price on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.64) per share. HC Wainwright also issued estimates for Celldex Therapeutics’ Q4 2023 earnings at ($0.74) EPS, FY2023 earnings at ($2.70) EPS and FY2024 earnings at ($3.32) EPS.
A number of other brokerages also recently issued reports on CLDX. StockNews.com raised Celldex Therapeutics to a “sell” rating in a research note on Friday, June 2nd. Cantor Fitzgerald dropped their price objective on Celldex Therapeutics from $55.00 to $54.00 in a research note on Friday, May 5th.
Celldex Therapeutics Trading Down 1.0 %
Shares of CLDX stock opened at $30.23 on Friday. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -12.60 and a beta of 2.10. The stock has a 50 day simple moving average of $35.39 and a 200-day simple moving average of $37.05. Celldex Therapeutics has a 12-month low of $27.01 and a 12-month high of $48.40.
Institutional Investors Weigh In On Celldex Therapeutics
Large investors have recently bought and sold shares of the stock. Gyon Technologies Capital Management LP grew its holdings in Celldex Therapeutics by 53.7% during the 4th quarter. Gyon Technologies Capital Management LP now owns 16,834 shares of the biopharmaceutical company’s stock valued at $750,000 after buying an additional 5,881 shares during the last quarter. Strs Ohio acquired a new stake in Celldex Therapeutics during the 4th quarter valued at $53,000. Monarch Partners Asset Management LLC acquired a new stake in Celldex Therapeutics during the 4th quarter valued at $2,027,000. Bank of Montreal Can acquired a new stake in Celldex Therapeutics during the 4th quarter valued at $1,322,000. Finally, Keybank National Association OH acquired a new stake in shares of Celldex Therapeutics during the fourth quarter worth $259,000.
About Celldex Therapeutics
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.
See Also
- Five stocks we like better than Celldex Therapeutics
- How to Use the MarketBeat Stock Split Calculator
- Investing in Coffee: 3 Great Strategies to Consider
- What is Short Interest? How to Use It
- 5 Best Stocks to Buy in a Bear Market
- What is a Stock Market Index and How Do You Use Them?
- 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
